ATE512364T1 - Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha - Google Patents

Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha

Info

Publication number
ATE512364T1
ATE512364T1 AT03784692T AT03784692T ATE512364T1 AT E512364 T1 ATE512364 T1 AT E512364T1 AT 03784692 T AT03784692 T AT 03784692T AT 03784692 T AT03784692 T AT 03784692T AT E512364 T1 ATE512364 T1 AT E512364T1
Authority
AT
Austria
Prior art keywords
adhesion
amino acid
platelet
gpibα
switch loop
Prior art date
Application number
AT03784692T
Other languages
English (en)
Inventor
Eric Huizinga
Groot Philip De
Shizuko Tsuji
Roland Romijn
Marion Schiphorst
Jan Sixma
Piet Gros
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Application granted granted Critical
Publication of ATE512364T1 publication Critical patent/ATE512364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Push-Button Switches (AREA)
  • Electronic Switches (AREA)
  • Liquid Crystal (AREA)
AT03784692T 2002-08-07 2003-08-06 Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha ATE512364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078277 2002-08-07
PCT/NL2003/000564 WO2004015425A1 (en) 2002-08-07 2003-08-06 Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha

Publications (1)

Publication Number Publication Date
ATE512364T1 true ATE512364T1 (de) 2011-06-15

Family

ID=31502790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784692T ATE512364T1 (de) 2002-08-07 2003-08-06 Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha

Country Status (5)

Country Link
US (1) US7771724B2 (de)
EP (1) EP1527346B1 (de)
AT (1) ATE512364T1 (de)
AU (1) AU2003251238A1 (de)
WO (1) WO2004015425A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0323728D0 (en) * 2003-10-10 2003-11-12 Royal College Of Surgeons Ie Peptidomimetics and uses thereof
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
CA2591914C (en) * 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
ES2197210T3 (es) * 1994-11-30 2004-01-01 Ajinomoto Co., Inc. Agente antitrombotico y anticuerpos monoclonales contra el factor von willebrand.
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6350860B1 (en) 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DK1027439T3 (da) * 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
ATE535154T1 (de) * 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
HUP9900956A2 (hu) * 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6251393B1 (en) * 1998-10-23 2001-06-26 The Brigham And Women's Hospital, Inc. Conformation-specific anti-von Willebrand Factor antibodies
EP1002861A1 (de) 1998-10-26 2000-05-24 Unilever Plc Antigenbindungsproteine mit einer Kopplung, die die strukturelle Beweglichkeit einschränkt
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
EP1190260B1 (de) 1999-07-05 2011-01-26 K.U. Leuven Research & Development Von willebrand-faktor-aktivitätsnachweis
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20050136056A1 (en) * 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558645B1 (de) 2002-11-08 2011-07-27 Ablynx N.V. Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
WO2008049881A2 (en) 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases

Also Published As

Publication number Publication date
US7771724B2 (en) 2010-08-10
EP1527346A1 (de) 2005-05-04
EP1527346B1 (de) 2011-06-08
WO2004015425A1 (en) 2004-02-19
AU2003251238A1 (en) 2004-02-25
US20050192224A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
AU2003251238A1 (en) Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
ES2333598T5 (es) Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
AU2003250825A1 (en) Inhibitors of glycoprotein vi
CY1118467T1 (el) Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης
PE20010613A1 (es) Antagonistas de la hormona concentradora de la melanina
EA201792485A2 (ru) Комплекс фактора viii с xten и белком-фактором фон виллебранда и его применение (варианты)
DK1759709T3 (da) Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
ATE438624T1 (de) 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
EP1625209A4 (de) Chimärische immunglobulin-monomer-dimer-hybride
NO20011386L (no) Nye fremgangsmåter for fremvisning av (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
DE60200194D1 (de) Freisetzungssystem von cyclopropenderivaten
UA84432C2 (ru) Очищенные пептиды и соединения, которые их содержат
ES2147210T3 (es) Derivados de acido acetico como medicamentos.
CY1109487T1 (el) Ανταγωνιστες τυπου ουριας του υποδοχεα p2y1 χρησιμοι στην αγωγη θρομβωτικων καταστασεων
HUT77122A (hu) Cseppfolyós immunglobulinkészítmények
ES2061502T3 (es) Nuevos n-heterociclos biciclicos puenteados.
EP1584627A4 (de) Dimerisiertes peptid
EA202190264A1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
DE59605649D1 (de) Polymerisationsfähige derivate von polyamiden
FI941457A0 (fi) Verihiutaleglyproteiini IIb/IIIa:n inhibiittoreina käyttökelpoisia syklisiä yhdisteitä
ATE230398T1 (de) Substituierte heterocyklische derivate, verwendbar als plättchenaggregationshemmstoffe
DE602006016765D1 (de) Verbesserte sgp 130Fc Dimere
DE60220085D1 (de) Verfahren zum verkleben von holzmaterialien
ES2169080T3 (es) Inhibidor de la agregacion de plaquetas estimulada por colageno.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties